Form 4: InfuSystem Holdings CEO Richard Dilorio Reports Stock Transactions
SEC Form 4 Filing
Richard Dilorio, CEO of InfuSystem Holdings, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units.
Summary
- Richard Dilorio, the CEO of InfuSystem Holdings, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- On May 17, 2024, Dilorio acquired 11,659 shares of common stock through the vesting of performance-based restricted stock units and 224,817 stock options.
- He also disposed of 5,639 shares to cover tax liabilities associated with the vesting of restricted stock units on the same day at a price of $6.44.
- On May 18, 2024, Dilorio acquired 14,103 shares of common stock through the vesting of restricted stock units and disposed of 6,819 shares to cover tax liabilities at a price of $6.44.
- Following these transactions, Dilorio directly owns 440,121 shares of InfuSystem Holdings common stock and 49,685 restricted stock units.
- The stock options vest in four equal annual installments beginning May 17, 2025, and expire on May 17, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected, with no clear positive or negative implications for the company's performance.
Positives
- The vesting of restricted stock units and stock options indicates that performance targets were met, which could be seen as a positive signal.
Negatives
- The disposal of shares to cover tax liabilities, while routine, slightly reduces Dilorio's overall stake in the company.
Risks
- Future stock transactions by Dilorio could impact the market price of InfuSystem Holdings shares.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a long-term commitment from the CEO.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. This filing is specific to InfuSystem Holdings and its CEO.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
- Similar filings are expected from executives at comparable companies in the medical device and healthcare services sectors, such as Option Care Health (OPCH) or BioScrip (BIOS), allowing investors to monitor insider sentiment and potential alignment with company performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 05/17/2022 | Date performance-based restricted stock units were granted. |
| 05/17/2024 | Date of multiple transactions: vesting of restricted stock units, acquisition of stock options, and disposal of shares for tax liability. |
| 05/18/2024 | Date of restricted stock units cliff vesting and disposal of shares for tax liability. |
| 05/17/2025 | First vesting date for the acquired stock options. |
| 05/17/2034 | Expiration date for the acquired stock options. |
| 05/21/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.